GlobeImmune Inc. announced earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported net income of $0.9 million for the three months ended September 30, 2015, compared to a net loss of $6.4 million for the same period in 2014. The company's net income for the three months ended September 30, 2015 is due to the license revenue from Celgene licensing GI-6207 and losses have resulted principally from costs incurred in its discovery and development activities.

For the nine months, the company's net cash used in operating activities for the first nine months ended September 30, 2015 was $5.7 million, compared to $8.0 million for the same period in 2014.